Provider review
Magnolia Regenerative Medicine Review: A Catalog That Makes Its Claims by Filing Them
We loaded all 24 of Magnolia's product pages expecting the usual paragraph of "may help support" and found none of them has one. There is no description, no benefits panel, no mechanism — just a name, a price, a storage line and a category. That is not restraint. Filing BPC-157 under "Injury and recovery" tells a buyer what it is for without writing a sentence anyone could quote back, and the footer of every one of those pages calls the whole catalog "evidence-based treatments".
Twenty-four products, no product descriptions, and a category label doing the work a claim would have to defend.
Worth trusting if
- You are buying kisspeptin, the one item here whose category points at real randomized human evidence
- You want a peptide catalog with prices visible before an intake, which these are
- You are near Ville Platte or Lake Charles and want an in-person option
Be skeptical if
- You want to know what a product is supposed to do, because no product page says
- You expect to cancel by the route the contract names, because that address is on a domain with no DNS
- You are budgeting from the advertised GLP-1 figure, which is a prepay rate a first-time patient cannot get
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens magnoliaregen.com. A link is not a recommendation to take anything.
Provenance
What Magnolia Regenerative Medicine actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- BPC-157 (injection, 3mg/mL) — $143 to start, the highest of the single-peptide injections.
- TB-500 (injection, 3mg/mL) — $152 to start; the same figure buys any of the three BPC-157 combination vials.
- Epithalon (injection, 2mg/mL) — $135 to start; the GHK-Cu blend that contains it costs more.
- MOTS-C (injection, 2mg/mL) — $135 to start.
- Thymosin Alpha-1 (injection, 1mg/mL) — $135 to start.
- Kisspeptin (injection, 1mg/mL) — $135 to start, the same as PT-141 in the same category.
- Sermorelin (injection) — $135 to start; tesamorelin, filed under the same three categories, is $161.
- Tirzepatide + B12 (injection) — Advertised from $179, which is a prepay figure rather than a monthly rate; the month-to-month plan found by walking the intake is $199.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 8 products reviewed here. The evidence belongs to the molecule, not to Magnolia Regenerative Medicine.
6
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Magnolia Regenerative Medicine’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
BPC-157 (injection, 3mg/mL)BPC-157 · Compounded (503A)No trial supports this claim
“Injury and recovery. [The product page carries no description. Its only statement of purpose is that category label, alongside the footer text on every page: "…dedicated to helping you achieve optimal health and wellness through evidence-based treatments and personalized care plans."]”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 1 only
What the trials show for BPC-157
- NCT02637284 — Phase 1, unknown status, n=42. The registry record for BPC-157 in humans sits at phase 1 — the stage that establishes tolerability, not effect — and its status is unknown rather than completed.
Filing a molecule under "Injury and recovery" is an indication claim; it just is not a sentence. Six of the twenty-four products in this catalog contain BPC-157, all six sit in that category, and the human record for the molecule is one phase 1 study whose status is unknown. Phase 1 asks whether a dose is tolerated, not whether an injury heals faster. The footer's "evidence-based treatments" then covers this page too.1
TB-500 (injection, 3mg/mL)TB-500 (thymosin beta-4 fragment) · Compounded (503A)No trial supports this claim
“Injury and recovery. [No description on the product page; the category label is the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 1 only
- NCT07487363 — Phase 1/Phase 2, recruiting, n=80. TB-500 itself, recruiting rather than reporting. The larger thymosin beta-4 program is a different molecule at a different stage.
The one registered study of TB-500 is recruiting, so no human efficacy result for recovery exists yet to place it in this category on. An unfinished literature is not a hostile one, and it is not support either. Note also that TB-500 is a fragment of thymosin beta-4 rather than the whole molecule, which matters because the larger thymosin beta-4 program is sometimes cited as though it were the same thing.2
Epithalon (injection, 2mg/mL)Epithalon · Compounded (503A)No trial supports this claim
“Injury and recovery. [No description on the product page; the category label is the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returned zero studies for "Epithalon", zero for the spelling "Epitalon" and zero for "Epithalamin" — no registered trial of this molecule exists anywhere in the registry, for any indication, under any spelling. In PubMed, a search restricted to the randomized-controlled-trial publication type returns zero records. The randomized literature a looser search surfaces tests EPITHALAMIN, a peptide extract of bovine pineal gland rather than the synthetic tetrapeptide, and comes from a single research group.
This is the sharpest test of what a category label does. Epithalon has no registered trial anywhere, under any of its three spellings, for anything — and it is filed under "Injury and recovery" beside molecules that at least have a phase 1 record, on a page whose footer calls the catalog evidence-based. Fifteen of the twenty-four products sit in that one category, and a buyer scanning it has no way to tell that this one has nothing behind it while BPC-157 has a little.3
MOTS-C (injection, 2mg/mL)MOTS-c · Compounded (503A)No trial supports this claim
“Cognitive Health, Injury and recovery, Anti-aging, Overall Wellness. [No description on the product page; four category labels are the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists for a metabolic outcome.
Four categories is the most any product in this catalog carries, and it is the widest gap on the page between what is filed and what is known. The one registered trial is recruiting 120 participants for a metabolic outcome and has not reported. Cognition, recovery, aging and wellness are four separate promises, none of which that trial is even designed to answer.4
Thymosin Alpha-1 (injection, 1mg/mL)Thymosin alpha-1 · Compounded (503A)Claim reaches past the trials
“Overall Wellness. [No description on the product page; the category label is the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 3 trials
- NCT02867267 TESTS — Phase 3, completed, n=1,106. Thymosin alpha-1 in SEPSIS — completed phase 3, 1,106 critically ill patients. The strongest evidence this molecule has, in a population nobody joins voluntarily.
Searched live on 2026-09-01, thymosin alpha-1 has 64 randomized-trial records in PubMed and 64 registered studies — genuinely substantial, and read rather than counted they are hepatitis B, sepsis, severe pancreatitis, cirrhosis and cancer immunotherapy. "Overall Wellness" is the vaguest label in the taxonomy and it is attached to the molecule with the strongest evidence in the catalog, all of it collected in seriously ill patients. Modulating immunity in intensive care is a different thing from wellness in a well adult.5
Kisspeptin (injection, 1mg/mL)Kisspeptin · Compounded (503A)Claim matches the trials
“Sexual wellness. [No description on the product page; the category label is the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 1 only
- NCT00914823 Kisspeptin Administration in the Adult — Phase 1, completed, n=256. The largest completed registry record of giving kisspeptin to adults. Its endpoints are reproductive-hormone physiology, not sexual desire — no registered trial has studied this molecule for the use it is filed under here.
Searched on 2026-09-01, ClinicalTrials.gov holds 45 kisspeptin studies and READING them rather than counting them, not one is about sexual desire: they are reproductive endocrinology — hypogonadotropic hypogonadism, delayed puberty, hypothalamic amenorrhea, hyperprolactinemia. A control search for tirzepatide in the same pass returned 293 records, so the registry was answering. The sexual-desire evidence exists outside the registry: PubMed returns 36 kisspeptin records under the randomized-controlled-trial publication type, of which eleven mention sexual, libido or desire, and reading those eleven leaves five relevant human studies from one academic group — randomized placebo-controlled crossover trials in men and in women with hypoactive sexual desire disorder, published between 2017 and 2023, with brain-activation and penile-tumescence endpoints.
This is the one place in the catalog where the label points at something real, and it is worth saying so plainly. Randomized placebo-controlled trials have given kisspeptin to men and to women diagnosed with hypoactive sexual desire disorder and measured a difference. "Sexual wellness" does not reach past that. Two boundaries a buyer should still hold: those studies measured brain activation and physiological arousal rather than desire tracked over time, and none of them is in the trial registry at all — the evidence is in the journals, and a registry search for this use returns nothing.6
Sermorelin (injection)Sermorelin · Compounded (503A)No trial supports this claim
“Injury and recovery, Muscle growth/strength, Weight loss. [No description on the product page; three category labels are the only statement of purpose.]”
Read on the Magnolia Regenerative Medicine site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery, muscle growth or weight loss in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
Three categories, and weight loss is the one to notice. Sermorelin sits in the same "Weight loss" bucket as compounded tirzepatide, which has one of the largest trial programs in modern medicine, on a site whose homepage advertises a 22% figure. Nineteen randomized sermorelin trials exist and not one measured weight.7
Tirzepatide + B12 (injection)Tirzepatide · Compounded (503A)Claim reaches past the trials
“Tirzepatide Can Help You Lose 22% of Your Body Weight”
Read on the Magnolia Regenerative Medicine site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks, adults with obesity or overweight and no diabetes. Mean weight reduction of 20.9% at the 15mg dose in the efficacy estimand; the higher figures quoted in marketing come from the on-treatment analysis.
The number is close to a real one and it belongs to a different product at a different dose. SURMOUNT-1's 22.5% comes from the on-treatment analysis of BRANDED tirzepatide at 15mg, the top of a five-step titration, over 72 weeks. Magnolia sells a COMPOUNDED tirzepatide-plus-B12 preparation whose plans start at 2.5mg weekly — the lowest step, which no trial has reported a weight result for — and the headline attaches the ceiling of the branded trial to it without naming the dose, the duration or the word compounded. A compounded preparation is not the trial drug and has not been reviewed by FDA for safety, effectiveness or quality.8
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. We searched nineteen pages for every term a compounder is normally identified by — the two compounding categories, the two pharmacy accreditation bodies, the phrase "compounded by" and the prescriber identifier — across the homepage, the weight-loss and product pages, both GLP-1 product pages, the GLP-1 landing page, the FAQ and ten FAQ answer pages, the terms, the privacy policy, and the about, membership, locations and contact pages. Every one returned nothing. The only wording offered is "highly accredited, top-tier compounding pharmacies" and, in the four-step process panel, "our US FDA-Inspected pharmacies" — a phrase that describes an inspection status rather than an approval, and confers no quality finding on any product. The prescribing practice is not named either: the Terms state that "Magnolia Regenerative Medicine does NOT own the practices, nor does Magnolia Regenerative Medicine employ the clinicians that treat you. Magnolia Regenerative Medicine is NOT a healthcare provider." No individual clinician is named anywhere on the site. The medical intake runs on Wizlo, a third-party platform reached from every product page's "Start Intake Form" button, which is never named to the reader.
Read on the Magnolia Regenerative Medicine site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any of the 24 products. The nearest thing to a quality claim is "our US FDA-Inspected pharmacies", which states that a facility is subject to inspection rather than that any product has been evaluated — compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The footer LegitScript seal is genuine in one narrow sense and not in another: certificate 4395819 returns a real image while two invented certificate ids return 403 through the same request, so the id is issued — but the seal's own alt text reads "Verify Approval for www.magnoliaregenerative.com", and that domain has no DNS records at all.
Read on the Magnolia Regenerative Medicine site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
"We provide telemedicine care in the following 26 states (including Washington D.C.)": Arizona, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois, Indiana, Iowa, Kentucky, Maine, Nevada, New Hampshire, New Mexico, New York, North Dakota, Ohio, Rhode Island, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin. Louisiana is not on that list, which is worth noticing because both of the company's clinics are in Louisiana and the site directs Louisiana readers to an in-person visit instead.
Read the full licensing claim
No clinician is named on the site — not a medical director, not a prescriber, not an advisory panel. The Terms state that the company does not own the practices, does not employ the clinicians and is not a healthcare provider. The entity is Magnolia Regenerative Medicine Health, LLC, with governing law and exclusive venue in Nevada, while both clinics are in Louisiana and no corporate address is published.
Read on the Magnolia Regenerative Medicine site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Every peptide price is visible on the catalog before any account, intake or questionnaire.
- Its kisspeptin sits in a category the randomized human literature actually supports, which is rare in this catalog and rare in this market.
- The Terms are unusually direct about what the company is not: it does not own the practices, does not employ the clinicians, and is not a healthcare provider.
Show 3 more
- Two physical clinic addresses are published, with a working phone number and a working support address.
- Its LegitScript certificate id is genuine — two invented ids return 403 through the same request.
- No FDA warning letter against Magnolia Regenerative Medicine or the entity behind it.
- Not one of the 24 product pages carries a description, a mechanism or a benefits statement — the category label is the only statement of purpose.
- The footer of all 24 calls the catalog "evidence-based treatments", including Epithalon, which has no registered trial under any spelling.
- The cancellation address named in the Terms is on magnoliaregenerative.com, a domain with no DNS records, so mail to it cannot be delivered.
Show 7 more
- The same Terms require written notice at least 24 hours before renewal to avoid the next charge.
- The LegitScript seal's alt text points at that same dead domain.
- "Tirzepatide Can Help You Lose 22% of Your Body Weight" attaches a branded 15mg trial ceiling to a compounded preparation whose plans start at 2.5mg.
- The advertised "Starting at" GLP-1 figures are prepay rates, not monthly ones, and a first-time patient is offered a higher titration plan instead.
- No pharmacy is named; a census of six standard terms across nineteen pages returned zero hits for all six.
- No clinician is named anywhere — no medical director, no prescriber, no advisory panel.
- Louisiana is absent from the 26-state telehealth list although both clinics are in Louisiana.
Verdict
The bottom line
The most useful thing to understand about this catalog is what it does not contain. Twenty-four product pages, no product descriptions — so the indication is asserted by which folder a molecule is filed in, and a category cannot be quoted back the way a sentence can. Read the categories as the claims they are, notice that Epithalon and thymosin alpha-1 sit in the same taxonomy despite one having no registered trial and the other having 64, and get cancellation instructions in writing before you subscribe, because the address the contract names is on a domain that cannot receive mail.
Opens magnoliaregen.com. A link is not a recommendation to take anything.
Twenty-four pages, zero descriptions
We loaded every product page in Magnolia's catalog — all 24 under `/product/catalog/`, enumerated off the catalog index rather than sampled — expecting the paragraph of hedged benefits that every other seller in this market writes.
There isn't one. Here is a complete product page, in full:
BPC-157 · Injection · Starting at $143 · Monthly & quarterly options available · Start Intake Form
CATEGORIES: Injury and recovery · TYPE: Injectable · STORAGE: Refrigerated
That is the entire page. No description, no mechanism, no benefits panel, no "may help support".
It is tempting to read that as restraint. It isn't, quite.
Full analysis — 5 more sectionsThe claim is the filing · "Evidence-based treatments" · The 22% headline · The address that cannot receive mail · What the advertised price is
The claim is the filing
"Injury and recovery" is a statement about what BPC-157 is for. So is filing kisspeptin under "Sexual wellness", thymosin alpha-1 under "Overall Wellness", and sermorelin under "Weight loss" alongside compounded tirzepatide.
The difference between a category and a sentence is that a sentence can be quoted back. A taxonomy conveys the same indication and leaves nothing to defend.
And the taxonomy flattens exactly the distinction a buyer needs. Look at the "Injury and recovery" shelf:
| Product | Human evidence for that category | |---|---| | BPC-157 | One phase 1 study, status unknown | | TB-500 | One study, recruiting | | Epithalon | No registered trial, any spelling, any indication | | GHK-Cu | Small completed topical dermatology work | | CJC/Ipamorelin | — |
Same shelf, same price band, no way to tell them apart.
"Evidence-based treatments"
The footer of all 24 pages reads:
"Our team of experienced healthcare professionals is dedicated to helping you achieve optimal health and wellness through evidence-based treatments and personalized care plans."
That sentence is on the Epithalon page. Searched under all three spellings — Epithalon, Epitalon, Epithalamin — ClinicalTrials.gov returns zero studies, and PubMed returns zero records under the randomized-controlled-trial publication type. 3
The 22% headline
The homepage's weight-loss card reads: "Tirzepatide Can Help You Lose 22% of Your Body Weight".
The number is nearly right and it belongs to something else. SURMOUNT-1 ran 72 weeks in 2,539 adults and reported a 20.9% mean reduction at 15mg in its efficacy estimand; the ~22% figure comes from the on-treatment analysis. 8 Fifteen milligrams is the top of a five-step titration of branded tirzepatide.
Magnolia sells a compounded tirzepatide-plus-B12 preparation, and its plans start at 2.5mg weekly — the lowest step, for which no trial has reported a weight result. The headline names no dose, no duration, and not the word compounded.
The address that cannot receive mail
Magnolia's Terms give exactly one route to cancel:
"You must terminate your Membership with written notice at least 24-hours before it renews in order to avoid being charged for the next billing cycle."
The address they give for that notice is on magnoliaregenerative.com.
That domain has no DNS records — no A record, no MX, no NS, no SOA — while the live site, magnoliaregen.com, resolves normally with Google mail servers. Mail to the contractual cancellation address cannot be delivered.
The same dead domain is the target of the footer's LegitScript seal alt text and of three contact lines in the FAQ.
There is a working support address on the live domain, and a working phone number. Use those, and keep the confirmation.
What the advertised price is
"Starting at $99" for semaglutide and "Starting at $179" for tirzepatide are not monthly rates. They are $297.00 ÷ 3 and $537.00 ÷ 3 — the per-month cost of a three-month prepayment.
Walking the intake four times, the month-to-month plans are $119.00 and $199. And a first-time patient, answering honestly that this would be their first course, is offered a titration plan at a higher figure again.
Questions
Frequently asked questions
Why don't the product pages say what anything does?
They genuinely don't — we checked all 24. Each page carries a name, a route, a storage line, a price and one or more category labels, and nothing else. The category is doing the work: filing BPC-157 under "Injury and recovery" states an indication without writing a sentence that could be quoted back.
Which product here has the best evidence?
Two, for different reasons. Kisspeptin's category is the one that points at real randomized human trials — placebo-controlled crossover studies in men and women with hypoactive sexual desire disorder, published 2017 to 2023, though with brain-activation rather than desire-over-time endpoints, and no registered trial of that use exists. Thymosin alpha-1 has far more trials, 64 of them, but read rather than counted they are hepatitis B, sepsis, pancreatitis and cancer immunotherapy, and it is filed here under "Overall Wellness".
Which has the least?
Epithalon. Searched under all three spellings — Epithalon, Epitalon and Epithalamin — ClinicalTrials.gov returns zero registered studies for any indication, and PubMed returns zero randomized-controlled-trial records. It sits on the same shelf, in the same price band, as molecules that have a phase 1 record.
Can I really lose 22% of my body weight?
That figure comes from SURMOUNT-1's on-treatment analysis of branded tirzepatide at 15mg over 72 weeks. Magnolia sells a compounded tirzepatide-plus-B12 preparation and its plans start at 2.5mg weekly, the lowest titration step, for which no trial has reported a weight result. A compounded preparation is not the trial drug and has not been reviewed by FDA for safety, effectiveness or quality.
How do I cancel?
Not by the route the contract names. The Terms require written notice at least 24 hours before renewal and give an address on magnoliaregenerative.com — a domain with no DNS records, where mail cannot be delivered. There is a working support address and a working phone number on the live site. Use those, and keep written confirmation.
Which pharmacy compounds these?
None is named. We searched nineteen pages for every term a compounder is normally identified by — the two compounding categories, the two pharmacy accreditation bodies, the phrase "compounded by" and the prescriber identifier — and every one returned nothing. The site offers "highly accredited, top-tier compounding pharmacies" and "our US FDA-Inspected pharmacies" — the second describes an inspection status, not an approval of anything you would receive.
Does Magnolia hold an FDA warning letter?
No FDA warning letter. We searched FDA's warning-letter database on September 1, 2026 for "Magnolia Regenerative", "Magnolia Regenerative Medicine" and "Magnolia Regenerative Medicine Health", and every one came back empty. Searching the bare word "Magnolia" does return a 2021 letter — to Magnolia Medical Technologies, Inc., a Seattle blood-culture device company with no connection to this business, matching on neither domain nor address. It is not this company's letter.
Glossary
Key terms
Show definitions
- Efficacy estimand
- The pre-specified analysis of what a trial drug does across everyone randomized to it, including participants who stopped early. The on-treatment analysis, which counts only those still taking the drug, usually produces a larger number — and it is usually the number marketing quotes.
- NXDOMAIN
- A DNS response meaning the domain does not exist — no address record, no mail servers, nothing. A contractual notice address on such a domain cannot receive mail.
Compare
Others selling what Magnolia Regenerative Medicine sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Magnolia Regenerative Medicine's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 8 sources
- US National Library of Medicine (2026). ClinicalTrials.gov record NCT02637284 — BPC-157 in humans, phase 1, status unknown, 42 participants. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). ClinicalTrials.gov record NCT07487363 — TB-500, phase 1/2, recruiting, 80 participants. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07487363
- US National Library of Medicine (2026). ClinicalTrials.gov searches for "Epithalon", "Epitalon" and "Epithalamin" — zero studies under every spelling; PubMed randomized-controlled-trial publication type — zero records. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Epithalon
- US National Library of Medicine (2026). ClinicalTrials.gov record NCT07505745 (MOTS-MET) — MOTS-c, phase 2, recruiting, 120 participants. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- Wu J, Zhou D, Deng C, et al. (2019). Effect of Thymosin α1 on Mortality in Patients With Severe Sepsis (TESTS) — completed phase 3, 1,106 participants. ClinicalTrials.gov NCT02867267. https://clinicaltrials.gov/study/NCT02867267
- Mills EG, Thurston L, Dhillo WS, et al. (2023). Randomized placebo-controlled trials of kisspeptin in men and in women with hypoactive sexual desire disorder, 2017–2023; ClinicalTrials.gov holds 45 kisspeptin studies, none for sexual desire (control: tirzepatide, 293 records, same pass). JAMA Network Open / ClinicalTrials.gov / PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=kisspeptin+AND+%22randomized+controlled+trial%22%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.